McKnight’s Senior Living September 29, 2022
An investigational drug showing promise in reducing cognitive decline in early Alzheimer’s disease is being hailed as having potential to “change the course” of the disease.
Initial results of a Phase 3 clinical trial of lecanemab announced late Tuesday are being hailed by some as a “major milestone” in Alzheimer’s disease treatments.
Japanese drugmaker Eisai and U.S. biotechnology company Biogen on Tuesday announced the positive results from the Clarity AD clinical trial of lecanemab. It is an investigational anti-amyloid beta antibody in the treatment of mild cognitive impairment due to Alzheimer’s disease and mild Alzhemier’s disease. Results will be presented Nov. 29 at the Clinical Trials on Alzheimer’s Congress.
“These are the most encouraging results in clinical trials treating...
Today's Sponsors
Today's Sponsor